A Phase 3 interventional study of clopidogrel (SR25990) in Arteriosclerosis, sponsored by Sanofi. Completed at 32 sites in 32 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-04-23.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Arteriosclerosis with a site in United States — 3 open to participants now, 4 under way, 1 of them phase 3. Arteriosclerosis · United States.
Among the 45 studies in Arteriosclerosis with a site in United States, this one has the largest enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2002, is one of 7 in phase 3, and was the 3rd registered.
157 studies on the registry are indexed under Arteriosclerosis; 18 are open to participants now.
Browse Arteriosclerosis studies →3 of the 45 studies in Arteriosclerosis with a site in United States are open now. Recruiting first, the newest first:
Teleflex · Sites in United States, France, Latvia and 1 more country
Ages 18–80
Fundación EPIC · Sites in United States, Belgium, Spain and 1 more country
Ages 18–85
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Arteriosclerosis studies recruiting now, 7 (50%) set no upper age limit and 3 (21%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15,603 is above the median of 109 across 104 interventional studies indexed under Arteriosclerosis.
Median enrollment 86 across the 36 interventional studies, 160 across the 8 observational. Of the 37 that completed or were terminated, 13 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 45 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Arteriosclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies in Arteriosclerosis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
RATIONALE:
OBJECTIVES:
TREATMENTS:
TREATMENT PLAN:
PRIMARY ENDPOINT:
STUDY EXECUTION:
STUDY TERRITORY:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Be at least 45 years old and comply with at least one of the four categories of inclusion criteria:
Major atherothrombotic risk factors
Minor atherothrombotic risk factors
and/or
EXCLUSION:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Occurrence of myocardial infarction,stroke or cardiovascular death.
severe bleeding
The record gives a start of Oct 2002 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel